bioRxivImmunology
FOXP3+ regulatory T cells use heparanase to access IL-2 bound to ECM in inflamed tissues
H. A. Martinez, I. Koliesnik, G. Kaber, N. Nagy, G. Barlow, B. A. Falk, J. K. Reid, C. O. Medina, A. Hargil, I. Vlodavsky, J.-p. Li, M. Perez-Cruz, S.-W. Tang, E. H. Meyer, L. E. Wrenshall, J. D. Lord, K. C. Garcia, T. D. Palmer, L. Steinman, G. T. Nepom, T. N. Wight, P. L. Bollyky, H. F. Kuipers
Abstract
FOXP3+ regulatory T cells (Treg) depend on exogenous IL-2 for their survival and function, but circulating levels of IL-2 are low, making it unclear how Treg access this critical resource in vivo. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) within the extracellular matrix (ECM) of inflamed central nervous system tissue. HPSE expression distinguishes human and murine Treg from conventional T cells and is regulated by the availability of IL-2. HPSE-/- Treg have impaired stability and function in vivo, including the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Conversely, endowing Treg with HPSE enhances their ability to access HS-sequestered IL-2 and their tolerogenic function in vivo. Together, these data identify novel roles for HPSE and the ECM in immune tolerance, providing new avenues for improving Treg-based therapy of autoimmunity. One-Sentence SummaryRegulatory T cells use heparanase to strip IL-2 bound to extracellular matrix within inflamed tissues, thereby supporting their homeostasis and function.
- organism: mouse
- organism: human
- assay: proteomics
- assay: imaging
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Treg cells maintain selective access to IL-2 and immune homeostasis despite substantially reduced CD25 function
E. T. Hayes, C. E. Hagan, D. J. Campbell·bioRxiv·Dec 24, 2019
- IL2 enhances ex-vivo expanded regulatory T cell persistence after adoptive transfer
S. N. Furlan, K. Singh, … L. S. Kean·bioRxiv·Oct 15, 2019
- Receptor-tethered orthogonal IL-2 enhances regulatory T cell therapy
Alyssa C. Indart, Huiyun Lyu, … Qizhi Tang·The Journal of Experimental MedicinePeer-reviewed·Jul 8, 2026
- Rapamycin rescues loss-of-function in blood-brain barrier-interacting regulatory T cells
- Coordinated IL-2 and TGF-β Signaling Activates Stable Regulatory T Cells and Promotes Immune Tolerance
Nicholas M. Jackson, Javier A. Carrero, … Richard J. DiPaolo·bioRxiv·Mar 27, 2026
- Intestinal lamina propria supports acquired eTreg suppressor function
Y. Gu, R. Bartolome-Casado, … F. Powrie·bioRxiv·Aug 26, 2022